These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 22071279

  • 1. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
    de Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, Saft C, Magnet MK, Sword A, Rembratt A, Tedroff J, MermaiHD study investigators.
    Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
    [Abstract] [Full Text] [Related]

  • 2. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
    Huntington Study Group HART Investigators.
    Mov Disord; 2013 Sep; 28(10):1407-15. PubMed ID: 23450660
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
    Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB, European Huntington's Disease Network, Huntington Study Group investigators.
    Lancet Neurol; 2019 Feb; 18(2):165-176. PubMed ID: 30563778
    [Abstract] [Full Text] [Related]

  • 4. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
    Huntington Study Group Reach2HD Investigators.
    Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
    Reilmann R, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, Piccini P, Schubert R, Loupe P, Wickenberg A, Borowsky B, Rynkowski G, Volkinshtein R, Li T, Savola JM, Hayden M, Gordon MF, LEGATO-HD Study Group.
    Lancet Neurol; 2024 Mar; 23(3):243-255. PubMed ID: 38280392
    [Abstract] [Full Text] [Related]

  • 6. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D.
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [Abstract] [Full Text] [Related]

  • 7. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW.
    Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
    [Abstract] [Full Text] [Related]

  • 8. Pridopidine for the Improvement of Motor Function in Patients With Huntington's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Chen S, Liang T, Xue T, Xue S, Xue Q.
    Front Neurol; 2021 May; 12():658123. PubMed ID: 34054700
    [Abstract] [Full Text] [Related]

  • 9. Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.
    Waters S, Tedroff J, Ponten H, Klamer D, Sonesson C, Waters N.
    J Huntingtons Dis; 2018 May; 7(1):1-16. PubMed ID: 29480206
    [Abstract] [Full Text] [Related]

  • 10. Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.
    McGarry A, Kieburtz K, Abler V, Grachev ID, Gandhi S, Auinger P, Papapetropoulos S, Hayden M.
    J Huntingtons Dis; 2017 May; 6(3):189-199. PubMed ID: 28826192
    [Abstract] [Full Text] [Related]

  • 11. Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial.
    van der Vaart T, Plasschaert E, Rietman AB, Renard M, Oostenbrink R, Vogels A, de Wit MC, Descheemaeker MJ, Vergouwe Y, Catsman-Berrevoets CE, Legius E, Elgersma Y, Moll HA.
    Lancet Neurol; 2013 Nov; 12(11):1076-83. PubMed ID: 24090588
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
    Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, Walsh JK, Krystal AD, Benca RM, Cohn M, Lines C, Roth T, Herring WJ.
    Lancet Neurol; 2014 May; 13(5):461-71. PubMed ID: 24680372
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
    Furr Stimming E, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D, Huntington Study Group KINECT-HD Collaborators.
    Lancet Neurol; 2023 Jun; 22(6):494-504. PubMed ID: 37210099
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.
    Lundin A, Dietrichs E, Haghighi S, Göller ML, Heiberg A, Loutfi G, Widner H, Wiktorin K, Wiklund L, Svenningsson A, Sonesson C, Waters N, Waters S, Tedroff J.
    Clin Neuropharmacol; 2010 Jun; 33(5):260-4. PubMed ID: 20616707
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Riluzole in Huntington's disease: a 3-year, randomized controlled study.
    Landwehrmeyer GB, Dubois B, de Yébenes JG, Kremer B, Gaus W, Kraus PH, Przuntek H, Dib M, Doble A, Fischer W, Ludolph AC, European Huntington's Disease Initiative Study Group.
    Ann Neurol; 2007 Sep; 62(3):262-72. PubMed ID: 17702031
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.